Replies to post #16841 on Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

Rachel McMinn....

Honestly, what I don't understand is how you can have a $2 value assigned to '113 and not have a down-side risk factor for '113.

If I were paying for that report, I'd be troubled by that.

[DewDiligence]

Rachel McMinn named top biotech analyst in WSJ’s 2011 “Best of Street” survey:

#msg-75461349

Phil Nadeau of Cowen, who was bullish on ARIA, was named the top pharma analyst in the same survey.